AKTS
Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
$18.75
+0.16% today
Updated 2026-04-30
Market cap
$1.03B
P/E ratio
—
P/S ratio
159.27x
EPS (TTM)
$-1.21
Dividend yield
—
52W range
$15 – $29
Volume
0.4M
Aktis Oncology, Inc. Common stock (AKTS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-929.00%
ROE
-29.40%
ROA
-15.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | — | $-1.22M | — | — | — |
| 2015 | $254834.00 | $-5.41M | 88.72% | -1,841.98% | -2,121.45% |
| 2017 | $16964.00 | $-9.11M | -548.93% | -58,704.12% | -53,691.58% |
| 2018 | $1.21M | $-21.74M | 15.60% | -1,844.39% | -1,799.76% |
| 2019 | $1.44M | $-30.88M | 29.80% | -1,906.93% | -2,139.92% |
| 2020 | $1.79M | $-40.87M | -34.86% | -1,789.83% | -2,283.13% |
| 2021 | $15.35M | $-59.19M | -26.95% | -394.50% | -385.63% |
| 2022 | $0.00 | $-17.93M | — | — | — |
| 2023 | $27.12M | $-28.64M | -11.49% | -128.29% | -105.60% |
| 2024 | $1.49M | $-43.98M | 100.00% | -3,500.34% | -2,957.63% |
| 2025 | $6.50M | $-63.73M | 100.00% | -1,149.52% | -980.93% |